RORgamma Modulators for Autoimmune Disease Treatment

Solution Overview

Problem

Current treatments for autoimmune and inflammatory diseases associated with RORγ, such as rheumatoid arthritis and psoriasis, lack effective small molecule ligands that can modulate RORγ activity, leading to inadequate therapeutic options.

Innovation Solution

Development of small molecule RORγ modulators that bind to the RORγ receptor, specifically compounds of Formula (1), which can act as agonists or antagonists to regulate RORγ activity, thereby treating or preventing RORγ-mediated diseases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for autoimmune and inflammatory diseases are used, then existing therapeutic options are available, but effective small molecule ligands that can modulate RORγ activity are lacking

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies parameter changes by developing small molecule compounds with specific chemical structures (Formula I) that can bind to RORγ and modulate its transcriptional activity. The compounds feature variable substituents (R1-R6, Ar, X, Y, Z) that can be optimized to achieve desired agonist or antagonist effects, enabling precise control of RORγ activity for therapeutic purposes

Inventive Principle:
Principle #35Parameter changes

2Object-affected harmful factors

If RORγ activity is reduced to treat autoimmune diseases, then immune response is shifted and symptoms are alleviated, but new therapeutic compounds must be developed

Engineering Contradiction:
Core Design Contradiction:
Object-affected harmful factorsVSEase of manufacture

Solution Approach 1:

The patent segments the therapeutic approach by creating a series of related compounds based on Formula I with different substituent patterns. This modular structure allows systematic optimization of individual compounds for specific disease indications while maintaining the core mechanism of RORγ modulation, facilitating both development and manufacturing

Inventive Principle:
Principle #1Segmentation

3Reliability

If small molecule RORγ modulators are developed, then effective treatment options are created, but compound structure complexity increases

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent achieves universality by designing a core molecular framework (Formula I) that can function as both agonist and antagonist depending on substituent configuration. This multi-functional design allows a single compound series to address multiple therapeutic needs (different autoimmune and inflammatory conditions) without requiring entirely separate molecular architectures

Inventive Principle:
Principle #6Universality (Multi-functionality)

Data Source

PatentEP2542537B1Novel compounds for modulation of orphan nuclear receptor rar-related orphan receptor-gamma (ROR gamma, NR1f3) activity and for the treatment of chronic inflammatory and autoimmune disease
Publication Date: 2014.05.21
  • EP2542537B1 patent drawingFigure 1a~1b
  • EP2542537B1 patent drawingFigure 1c
  • EP2542537B1 patent drawingFigure 2a

AI summary

The invention provides modulators for the orphan nuclear receptor ROR? and methods for treating ROR? mediated diseases by administrating these novel ROR? modulators to a human or a mammal in need thereof. Specifically, the present invention provides compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.